Persones / Equip Humà

Maite Begoña Gorostegui Obanos

Buscador de publicacions

Publicacions

  • Varo A, Castañeda-Heredia A, Chamorro S, Muñoz JP, Gorostegui M, Celma MS, Lopez S, Simao M, Pérez-Jaume S and Mora J.

    Novel infusion strategy reduces severe adverse events caused by the anti-GD2 monoclonal antibody naxitamab

    Frontiers in Oncology . 13: 1164949-1164949. Nº de cites: 14

    [doi:10.3389/fonc.2023.1164949]

  • Mora J, Castañeda-Heredia A, Gorostegui M, Varo A, Pérez-Jaume S, Simao M, Muñoz JP, Garraus-Oneca M, Cristina Larrosa Espinosa, Salvador-Marcos N, Lavarino C, Krauel L and Mañe S.

    Naxitamab Combined with Granulocyte-Macrophage Colony-Stimulating Factor as Consolidation for High-Risk Neuroblastoma Patients in First Complete Remission under Compassionate Use-Updated Outcome Report

    Cancers . 15(9): . Nº de cites: 23

    [doi:10.3390/cancers15092535]

  • Castañeda-Heredia A, Gorostegui M, Miralles SL, ALICIA CHAMIZO BREMER, Patiño SC, Flores MA, Garraus-Oneca M, Lazaro JJ, Santa-María López V, Varo A, Muñoz JP and Mora J.

    How we approach the treatment of patients with high-risk neuroblastoma with naxitamab: experience from the Hospital Sant Joan de Deu in Barcelona, Spain

    ESMO Open . 7(2): 100462-100462. Nº de cites: 18

    [doi:10.1016/j.esmoop.2022.100462]

  • Soosay Raj T, Noble C, Gray A, Moreira DC, Lowe J, Gorostegui M, Anga G, Soma A, Santos MLD, Cross S, Luttrell E, Sullivan M, Cayrol J, Challinor J, Ranasinghe N, McLoone J and Wakefield CE.

    Mapping Childhood Cancer Care Services in Oceania: Methodological Lessons From the SIOP Global Mapping Programme.

    PEDIATRIC BLOOD & CANCER . : .

    [doi:10.1002/1545-5017.70579]